24 completed, 8 unknown, 6 terminated, 5 active not recruiting. 28 Phase 2, 16 Phase 1, 3 Not applicable, 2 Phase 3.
Follow Extensive Stage Small Cell Lung Cancer: new trials by email Literature Review of Extensive Stage Small Cell Lung Cancer trials Research Report on Extensive Stage Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER ALPS12, obinutuzumab - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Chugai Pharmaceutical | 122 | 2025-10-08 | 2026-02-06 |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) Tarlatamab, AB248 - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 380 | 2025-09-16 | 2026-09-25 |
| Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection - Extensive Stage Small Cell Lung Cancer | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2025-04-07 | 2026-04-28 |
| Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab - Extensive Stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Zhou Chengzhi | 10 | 2024-12-01 | 2024-10-15 |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Tarlatamab - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 220 | 2024-10-07 | 2026-06-26 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment Tarlatamab - Extensive Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Amgen | 32 | 2024-08-27 | 2026-10-21 |
| A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer Adebrelimab + chemotherapy, ±chest radiotherapy - Extensive Stage Small Cell Lung Cancer | Unknown | Hebei Medical University Fourth Hospital | 50 | 2024-03-26 | 2024-03-27 | |
| A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel - Extensive Stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | STCube, Inc. | 10 | 2024-02-13 | 2025-09-05 |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Hirva Mamdani | 84 | 2023-09-26 | 2026-04-29 |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC Tislelizumab, Anlotinib - Extensive Stage Small Cell Lung Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 21 | 2023-05-15 | 2023-06-09 |
| To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) - Extensive Stage Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Henlius Biotech | 200 | 2022-11-18 | 2025-10-21 |
| First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Tarlatamab, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer | Phase 1 | Active not recruiting | Amgen | 184 | 2022-08-24 | 2026-09-09 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE - Extensive Stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 55 | 2022-07-13 | 2026-08-19 |
| Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer Fluzoparil, Anlotinib - Extensive Stage Small Cell Lung Cancer | Phase 2 | Unknown | Liu Zhenhua | 50 | 2021-06-01 | 2021-06-21 |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Cisplatin, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Muhammad Furqan | 30 | 2021-04-20 | 2026-09-03 |
| a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer SHR-1210 - Extensive Stage Small Cell Lung Cancer | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 71 | 2021-04-01 | 2021-03-10 |
| Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC Camrelizumab; apatinib; carboplatin; etoposide - Extensive Stage Small Cell Lung Cancer | Phase 1 | Unknown | Zhou Chengzhi | 36 | 2021-01-27 | 2021-08-12 |
| Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide - Extensive Stage Small Cell Lung Cancer | Phase 1 | Unknown | Lee's Pharmaceutical Limited | 20 | 2020-03-08 | 2022-05-11 |
| Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer nab-paclitaxel, Topotecan - Extensive Stage Small Cell Lung Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 386 | 2020-01-31 | 2019-12-30 |
| A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC HLX10, carboplatin and etoposide, placebo - Extensive Stage Small Cell Lung Cancer | Phase 3 | Completed | Shanghai Henlius Biotech | 585 | 2019-09-12 | 2025-12-09 |
Showing 20 of 49. Sign in to see all of them.
Small Cell Lung Carcinoma (21) · Carcinoma, Non-Small-Cell Lung (8) · Lung Neoplasms (4) · Neoplasms (4) · Colonic Neoplasms (3) · Rectal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Genetic Diseases, Inborn (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma of Lung (1) · Anus Neoplasms (1)
Lung Diseases (22) · Neoplasms by Site (22) · Respiratory Tract Diseases (22) · Respiratory Tract Neoplasms (22) · Thoracic Neoplasms (22) · Bronchial Neoplasms (21) · Carcinoma, Bronchogenic (21) · Neoplasms (19) · Lung Neoplasms (18) · Neoplasms by Histologic Type (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (3) · Carcinoma (3)
Etoposide (14) · Carboplatin (10) · Cisplatin (8) · Topotecan (5) · AMG 757 (4) · Irinotecan (3) · atezolizumab (3) · durvalumab (3) · trioctyl phosphine oxide (3) · 7-hydroxystaurosporine (2) · Bevacizumab (2) · Drug Therapy (2) · Sirolimus (2) · anlotinib (2) · camrelizumab (2)
National Cancer Institute (NCI) (17) · Amgen (4) · Hunan Province Tumor Hospital (2) · Shanghai Henlius Biotech (2) · Wake Forest University Health Sciences (2) · Zhou Chengzhi (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chugai Pharmaceutical (1) · Eastern Cooperative Oncology Group (1) · Hebei Medical University Fourth Hospital (1) · Hirva Mamdani (1) · Lee's Pharmaceutical Limited (1) · Liu Zhenhua (1) · Muhammad Furqan (1)
United States (31) · China (13) · South Korea (4) · Canada (3) · Germany (3) · Japan (3) · Spain (3) · Turkey (Türkiye) (3) · Australia (2) · Belgium (2) · France (2) · Israel (2) · Poland (2) · Switzerland (2) · Taiwan (2)
Chengzhi Zhou, MD (2) · Ravi Salgia (2) · Yongchang Zhang, MD (2) · Afshin Dowlati (1) · Agustin Garcia (1) · Alan Sandler (1) · Anne Traynor (1) · Antonius Miller (1) · Barbara Gitlitz (1) · Charles Rudin (1) · Christian H Ottensmeier, MD, PhD (1) · David S. Schrump (1) · Glennwood Goss (1) · Hirva Mamdani, MD (1)
PMID 25490004, PMID 25002722, PMID 36166026, PMID 36685541, PMID 37020926, PMID 37580661, PMID 39848827, PMID 39962074, PMID 40932107, PMID 42240984
U10CA021115 (3), U10CA031946 (3), P30CA014236 (2), P30CA014520 (2), N01CM17102 (1), N01CM62203 (1), N01CM62205 (1), N01CM62209 (1), P30CA012197 (1), P30CA015083 (1), P30CA043703 (1), P30CA044579 (1), P30CA051008 (1), R01CA088972 (1), U01CA062491 (1)